Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PTI

Proteostasis Therapeutics (PTI) Stock Price, News & Analysis

Proteostasis Therapeutics logo

About Proteostasis Therapeutics Stock (NASDAQ:PTI)

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$22.42
52-Week Range
N/A
Volume
9,405 shs
Average Volume
1.04 million shs
Market Capitalization
$37.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Receive PTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTI Stock News Headlines

Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
See More Headlines

PTI Stock Analysis - Frequently Asked Questions

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01.

Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Rite Aid (RAD) and

Company Calendar

Last Earnings
11/16/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTI
Fax
N/A
Employees
44
Year Founded
N/A

Profitability

Net Income
$-59,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Book Value
$1.22 per share

Miscellaneous

Free Float
N/A
Market Cap
$37.57 million
Optionable
Not Optionable
Beta
1.16
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:PTI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners